EUVIMEDEUVIMED entdecken
Open Access

Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies

Lindsey A McAlarnen, Christina Small, Lauren Tostrud, Amy Y Pan, Beth Erickson, Meena Bedi, William H Bradley

Brachytherapy · 2023

DOI: 10.1016/j.brachy.2023.06.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2023. Verfasst von Lindsey A McAlarnen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI. Electronic address: lmcalarne…. Hauptthemen laut MEDLINE: Venous Thromboembolism, Genital Neoplasms, Female, Brachytherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Center for Research Resources, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Brachytherapy irradiation carries risks of both bleeding and venous thromboembolism (VTE). No screening or management recommendations for VTE in this setting have been developed. Our study aims to understand the incidence of VTE, compile published anticoagulation guidelines, and call for future guidelines to address thromboprophylaxis in this population. METHODS AND MATERIALS: A retrospective, single institution study of patients undergoing brachytherapy irradiation between 2012 and 2022 was undertaken. We analyzed 2 cohorts: 87 patients undergoing brachytherapy with an inpatient admission, and 66 patients assessed for risk of VTE or bleeding after discharge from an inpatient admission for brachytherapy. Caprini risk scores were calculated for each patient, and statistical analyses were performed. RESULTS: Eighty-seven patients were included, and 25% had a VTE diagnosis. Forty-seven (54%) of patients included underwent brachytherapy as definitive treatment of cervical cancer, and 16 (18%) received brachytherapy irradiation to treat recurrent endometrial cancer. In the cohort of 66 patients assessed for risk of VTE or bleeding after brachytherapy discharge, 23 (34.8%) were discharged with thromboprophylaxis, and 43 (65.2%) were discharged without thromboprophylaxis. None of the patients discharged on thromboprophylaxis were diagnosed with a VTE within 90 days of discharge after brachytherapy, whereas 3 of 43 (7%) discharged without thromboprophylaxis were diagnosed with a VTE, OR and 95% CI: 0.25 (0.01-5.29), p = 0.37. Of the 23 patients discharged on thromboprophylaxis, 1 was readmitted for bleeding OR and 95% CI: 5.8 (0.22-155.18), p = 0.29. The median Caprini score was 11. CONCLUSIONS: VTE is a common occurrence in patients undergoing brachytherapy. Patients undergoing brachytherapy irradiation who require inpatient admission represent a unique population, and specialty organizations should develop consensus recommendations to address these clinical challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismGenital Neoplasms, FemaleBrachytherapyHumansFemaleAnticoagulantsPostoperative ComplicationsRetrospective StudiesInpatientsNeoplasm Recurrence, LocalHemorrhageRisk Factors

Stichwörter der Autor:innen

AnticoagulationCervical cancerGynecologic malignanciesInterstitial brachytherapyPharmacologic prophylaxisVenous thromboembolism

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI. Electronic address: lmcalarnen@mcw.edu.
  • Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI.
  • Division of Quantitative Health Sciences, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.

Förderung

  • NCATS NIH HHS
  • National Center for Research Resources
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

McAlarnen, L. A., Small, C., Tostrud, L., Pan, A. Y., Erickson, B., Bedi, M., & Bradley, W. H. (2023). Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies. Brachytherapy. https://doi.org/10.1016/j.brachy.2023.06.002

Vancouver

McAlarnen LA, Small C, Tostrud L, Pan AY, Erickson B, Bedi M, et al. Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies. Brachytherapy. 2023. doi:10.1016/j.brachy.2023.06.002

BibTeX
@article{McAlarnen2023,
  author = {McAlarnen, Lindsey A and Small, Christina and Tostrud, Lauren and Pan, Amy Y and Erickson, Beth and Bedi, Meena and Bradley, William H},
  title = {Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies},
  journal = {Brachytherapy},
  year = {2023},
  doi = {10.1016/j.brachy.2023.06.002}
}
Kostenlos starten →